2-(6-Piperidin-1-ylpyridin-3-yl)-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-c]azepin-4-one | 1312412-63-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(6-Piperidin-1-ylpyridin-3-yl)-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-c]azepin-4-one
• 英文别名: 2-(6-piperidin-1-ylpyridin-3-yl)-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-c]azepin-4-one
• CAS: 1312412-63-7
• 化学式: C₁₇H₂₀N₄OS
• 分子量: 328.438
• InChiKey: HXVFXVCJKQGBHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-5,6-二氢-4H-苯并噻唑-7-酮 在 四(三苯基膦)钯 sodium azide 、 硫酸 、 sodium carbonate 、 copper(ll) bromide 、 亚硝酸异戊酯 作用下， 以 乙二醇二甲醚 、 乙醇 、 氯仿 、 水 、 乙腈 为溶剂， 反应 63.0h， 生成 2-(6-Piperidin-1-ylpyridin-3-yl)-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-c]azepin-4-one
  参考文献：
  名称：

  BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS

  摘要：

  本发明涉及新型的双环噻唑，它们是代谢型谷氨酸受体亚型5（“mGluR5”）的阳性别构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的疾病以及涉及mGluR5受体亚型的疾病。该发明还涉及包含这种化合物的药物组合物，制备这种化合物和组合物的方法，以及利用这种化合物和组合物预防和治疗涉及mGluR5的疾病的用途。

  公开号：

  US20120252800A1

文献信息

• [EN] BICYCLIC COMPOUNDS FOR DIAGNOSIS AND THERAPY<br/>[FR] COMPOSÉS BICYCLIQUES POUR DIAGNOSTIC ET TRAITEMENT
  申请人：AC IMMUNE SA

  公开号：WO2017153601A1

  公开（公告）日：2017-09-14

  The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (a-synuclein, A- synuciein, aSynuciein, A-syn, a-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease. The instant compounds are particularly useful in determining a predisposition to such a disorder, monitoring residual disorder, or predicting the responsiveness of a patient who is suffering from such a disorder to the treatment with a certain medicament. The present compounds can also be used to treat, alleviate or prevent a disorder or abnormality associated with alpha-synuclein aggregates.

  本发明涉及可以用于诊断、监测疾病进展或监测药物活性的化合物(I)的公式，该化合物可用于与α-突触核蛋白（α-突触核蛋白，A-突触核蛋白，aSynuciein，A-syn，a-syn，aSyn）聚集相关的一组疾病和异常，包括但不限于Lewy小体和/或Lewy神经纤维，如帕金森病。这些化合物特别有助于确定对这种疾病的易感性，监测残留疾病，或预测患有这种疾病的患者对某种药物治疗的反应性。这些化合物还可用于治疗、缓解或预防与α-突触核蛋白聚集相关的疾病或异常。
• [EN] BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS<br/>[FR] THIAZOLES BICYCLIQUES EN TANT QUE MODULATEURS ALLOSTÉRIQUES DES RÉCEPTEURS MGLUR5
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011073347A1

  公开（公告）日：2011-06-23

  The present invention relates to novel bicyclic thiazoles of formula (I) which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 ("mGluR5") and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

  本发明涉及公式（I）的新型双环噻唑，它们是代谢型谷氨酸受体亚型5（"mGluR5"）的阳性变构调节剂，并且适用于治疗或预防与谷氨酸功能障碍有关的疾病以及涉及mGluR5受体亚型的疾病。该发明还涉及包含这种化合物的药物组合物，用于制备这种化合物和组合物的方法，以及用于预防和治疗涉及mGluR5的疾病的这种化合物和组合物的用途。
• US9174953B2
  申请人：——

  公开号：US9174953B2

  公开（公告）日：2015-11-03
• BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS
  申请人：MacDonald Gregor James

  公开号：US20120252800A1

  公开（公告）日：2012-10-04

  The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.

  本发明涉及新型的双环噻唑，它们是代谢型谷氨酸受体亚型5（“mGluR5”）的阳性别构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的疾病以及涉及mGluR5受体亚型的疾病。该发明还涉及包含这种化合物的药物组合物，制备这种化合物和组合物的方法，以及利用这种化合物和组合物预防和治疗涉及mGluR5的疾病的用途。